US Market Report for Rheumatoid Arthritis Immunology Drugs 2018 - MedCore

Tuesday, November 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 6, 2017 /PRNewswire/ --

General Report Contents- Market Analyses include: Unit Sales, ASPs,

Market Value & Growth TrendsRead the full report: https://www.reportlinker.com/p05175235- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsCurrent
treatments of RA aim to relieve the symptoms of the disease and regain the maximum functionality of the damaged joint. There is no cure for rheumatoid arthritis. The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.DMARDs are a group of medications commonly used in patients with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. DMARDs work to reduce pain and inflammation, to prevent or minimize joint damage. They take effect over months and are not designed to provide immediate relief of symptoms.DMARDs can be prescribed along with nonsteroidal anti-inflammatory drugs and/or low-dose corticosteroids. Common DMARDs include methotrexate (Rheumatrex, Trexall, Otrexup, and Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine).Patients in more severe stages of the disease may need biologic response modifiers. These medications can block immune system chemical signals that lead to inflammation and joint damage. The biologic drugs include ORENCIA® (abatacept), HUMIRA® (adalimumab), Kineret® (Anakinra), CIMZIA® (certolizumab), ENBREL® (etanercept), SIMPONI® (golimumab), REMICADE® (infliximab), Rituxan® and MabThera® (rituximab) and Actemra® (tocilizumab).AbstractRheumatoid arthritis (RA) is a chronic systemic disease affecting joints, connective tissue, muscles, tendons and fibrous tissue. It is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints, leading to a painful swelling and destroys the cartilage and bone, resulting in permanent joint deformity.RA is one of the most disabling types of arthritis that causes joint pain, stiffness and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes RA can affect other organs, such as eyes, skin or even heart or lungs.Scope2014-2024Read the full report: https://www.reportlinker.com/p05175235 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-rheumatoid-arthritis-immunology-drugs-2018---medcore-300550603.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store